A world in which the responsible application of science and technology leads to better health for people and populations. We want science to work for health. We support the responsible development and ...

These plans have been a long time in the making. The intention to produce a strategy ‘to ensure the UK is able to offer a predictive, preventative and personalised health and care service for people ...

The UK is a recognised powerhouse for genomic science and medicine. Genomics England’s 100,000 Genomes Project is the largest sequencing project of its kind in the world and, building on these ...

Inter-CeBIL is the International Collaborative Biomedical and Innovation Law program involving the law faculties at Copenhagen, Cambridge, Harvard and select other partners. PHG Foundation is ...

The rapid development, approval and roll out of multiple vaccines against SARS-CoV-2, the virus that causes COVID-19, is an impressive achievement for science and healthcare. The virus genome was ...

The Wellcome Trust recently announced that they are funding a research programme to investigate synthetic human genomes, and Laura Blackburn, PHG Foundation’s Head of Science, had the opportunity to ...

On Friday the High Court ruled on the case of ABC v St George’s NHS Trust (and other NHS defendants). This is a significant decision with implications for a wide range of healthcare professionals ...

Widely regarded as a founder of cell free DNA (cfDNA) technology, Professor Dennis Lo is now pioneering investigation into the emerging science of fragmentomics. If you were at were at our recent ...

A recent consultation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) indicates a welcome new direction for public and patient involvement (PPI). The MHRA proposed new five-year ...

The UK is a global leader in genomic research and healthcare, with the NHS Genomic Medicine Service (NHS GMS) the first clinical service to offer whole genome sequencing as part of routine care for ...

Cost-utility studies provide critical information for the costs and benefits of using any new test, typically building on existing public health and screening programmes, within a defined population.

The optimism is not unfounded. In specific, well-defined clinical scenarios, polygenic scores are beginning to demonstrate some tangible utility. For cardiovascular disease, MI-GENES, a 10-year follow ...